Analysts Set Phreesia, Inc. (NYSE:PHR) Price Target at $30.54

Shares of Phreesia, Inc. (NYSE:PHR) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.54.

Several equities research analysts recently weighed in on PHR shares. Stephens reiterated an “overweight” rating and set a $28.00 price objective on shares of Phreesia in a research note on Friday, May 31st. Canaccord Genuity Group cut their price target on Phreesia from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 31st. KeyCorp lowered their price objective on Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Friday, May 31st. Finally, Truist Financial restated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Monday, July 1st.

Phreesia Price Performance

Shares of PHR opened at $25.39 on Monday. Phreesia has a 52 week low of $12.05 and a 52 week high of $30.70. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -11.70 and a beta of 0.93. The stock has a 50 day moving average of $22.47 and a 200-day moving average of $22.96.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Thursday, May 30th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.16. The firm had revenue of $101.20 million during the quarter, compared to the consensus estimate of $100.94 million. Phreesia had a negative net margin of 31.87% and a negative return on equity of 46.89%. The firm’s revenue was up 20.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.70) earnings per share. As a group, analysts forecast that Phreesia will post -1.16 EPS for the current year.

Insider Activity

In related news, SVP David Linetsky sold 1,820 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $43,206.80. Following the sale, the senior vice president now owns 202,218 shares of the company’s stock, valued at $4,800,655.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Chaim Indig sold 2,644 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total transaction of $62,768.56. Following the completion of the transaction, the chief executive officer now owns 1,219,361 shares in the company, valued at approximately $28,947,630.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP David Linetsky sold 1,820 shares of Phreesia stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $43,206.80. Following the completion of the transaction, the senior vice president now directly owns 202,218 shares in the company, valued at approximately $4,800,655.32. The disclosure for this sale can be found here. Insiders sold 15,227 shares of company stock worth $369,466 over the last three months. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Phreesia

Large investors have recently added to or reduced their stakes in the business. Raymond James & Associates acquired a new stake in shares of Phreesia during the 4th quarter valued at $226,000. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Phreesia by 18.5% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 17,927 shares of the company’s stock valued at $415,000 after purchasing an additional 2,805 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Phreesia by 1,987.3% during the fourth quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock valued at $34,000 after purchasing an additional 1,411 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Phreesia by 25.4% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 39,386 shares of the company’s stock valued at $912,000 after purchasing an additional 7,976 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Phreesia by 11.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,757 shares of the company’s stock worth $295,000 after purchasing an additional 1,324 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.